Phase 1-2, double-Blind, Placebo-controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to standard of Care for the Treatment of High-Risk patients with Respiratory Viral Infections After Hematopoietic Cell Transplant

Protocol No
ALLOVIR-P-106-001-RESP
Principal Investigator
Mehdi Hamadani
Phase
I/II
Summary
Find out more about the side effects (problems and symptoms) of an investigational drug for viral respiratory tract infection after a bone marrow transplant, ALVR106 and what doses of ALVR106 are safe for people to take.
Description
AlloVir P-106-001 Study in Patients Developing Respiratory Infections Post HSCT
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL